Abstracts tagged "giant cell arteritis"

Abstract Number: 0696 • ACR Convergence 2023
Association of Large-vessel Vasculitis with Inflammatory Bowel Diseases: A European Case-control Study
Francois Maillet¹, Yann Nguyen², Olivier Espitia³, Laurent Perard⁴, Carlo Salvarani⁵, Etienne Rivière⁶, Cécile-Audrey Durel⁷, Philippe GUILPAIN⁸, Luc Mouthon⁹, Anna Kernder¹⁰, Javier Loricera¹¹, Pascal Cohen¹², Isabelle Melki¹³, Claire De Moreuil¹⁴, Nicolas Limal¹⁵, Arsène Mekinian¹⁶, Nathalie Costedoat-Chalumeau¹⁷, Nathalie Morel¹², Jonathan Boutemy¹⁸, Loic Raffray¹⁹, Jean-Sébastien Allain²⁰, Valerie Devauchelle²¹, Isabelle Kone-Paut²², Marc Fabre²³, Marie Durel²⁴, Antoine Dossier²⁵, Sébastien Abad²⁶, Marcella Visentini²⁷, Adrien Bigot²⁸, Halil Yildiz²⁹, Olivier Fain³⁰, Maxime Samson³¹, Guillaume Gondran³², Vered Abitbol¹ and Benjamin Terrier³³, ¹Cochin Hospital, Paris, France, ²Department of Internal Medicine, Hôpital Beaujon, AP-HP, Clichy, France., Montmorency, France, ³CHU de Nantes, Nantes, France, ⁴CH Saint Hoseph Saint Luc, Lyon, France, ⁵Azienda USL -IRCCS di Reggio Emilia and Università di Modena e Reggio Emilia, Reggio Emilia, Italy, ⁶CHU Bordeaux, Bordeaux, France, ⁷CHU Lyon, Lyon, France, ⁸University of Montpellier, Montpellier, France, ⁹Hopital Cochin - Paris University, Paris, France, ¹⁰HHU Düsseldorf, Düsseldorf, Germany, ¹¹Hospital Universitario Marqués de Valdecilla, Santander, Spain, ¹²CHU Cochin, Paris, France, ¹³Hopital Robert Debré, Sérurier, France, ¹⁴CHU de Brest, Brest, France, ¹⁵AP-HP, Créteil, France, ¹⁶Department of Internal Medicine, Hôpital Saint-Antoine, AP-HP, Paris, France, ¹⁷Inserm DR Paris 5, Paris, France, ¹⁸CHU de Caen, Caen, France, ¹⁹CHU la Réunion, La Réunion, France, ²⁰CHU Rennes, Rennes, France, ²¹UBO, Brest, France, ²²Department of Pediatric Rheumatology, Reference Centre for Autoinflammatory Disorders CEREMAIA, Bicêtre Hospital, APHP, University of Paris Saclay, Paris, France, ²³CH Bourgoin-Jallieu, Bourgoin-Jallieu, France, ²⁴CH Metz, Metz, France, ²⁵AP-HP, Paris, France, ²⁶Avicenne Hospital, Bobigny, France, ²⁷Rome Hospital, Rome, France, ²⁸Tours Hospital, Tours, France, ²⁹Saint Luc Hospital, Bruxelles, Belgium, ³⁰Hopital SAINT ANTOINE APHP, Paris, France, ³¹Department of Internal Medicine and Clinical Immunology, Dijon University Hospital, Dijon, France, ³²Limoges Hospital, Limoges, France, ³³Department of Internal Medicine, Hôpital Cochin, AP-HP, Paris, France
Background/Purpose: The association of large vessel vasculitis (LVV), whether Takayasu arteritis (TA) or giant cell arteritis (GCA), with inflammatory bowel disease (IBD) is a rare…
Abstract Number: 1645 • ACR Convergence 2023
Aortic Dilatation and PET/CT Vascular Activity at Diagnosis and 5 Years in an Inception Giant Cell Arteritis (GCA) Cohort
Anthony Sammel¹, Ivan Ho Shon², Daniel Moses¹, Fredericks Stacey¹, Gita Mathur¹, Claudia Hillenbrand³, Edward Hsiao⁴, Schembri Geoffrey⁴, Rodger Laurent⁴ and Eva Wegner², ¹Prince of Wales Hospital, Randwick, Australia, ²The Prince of Wales Hospital, Sydney, Australia, ³University of NSW, Randwick, Australia, ⁴Royal North Shore Hospital, St. Leonards, Australia
Background/Purpose: Aortic dilatation is typically a late complication of giant cell arteritis (GCA) but there are no tools to risk stratify patients at the time…
Abstract Number: 2391 • ACR Convergence 2023
Epidemiology and Predictors of Relapse in Giant Cell Arteritis: Results of the ARTESER Register
Javier Narvaez¹, Jesús Sanchez-Costa², Iñigo Hernández-Rodríguez³, Rafael Benito Melero-Gonzalez⁴, Eugenio De Miguel⁵, Irene Monjo⁶, Maite silva díaz⁷, LUCIA SILVA FERNANDEZ⁸, Joaquin Maria Belzunegui Otano⁹, Jesus Alejandro Valero-Jaimes¹⁰, Clara Moriano Morales¹¹, Ismael González¹², Julio Sanchez Martin¹³, Tomas Almorza Hidalgo¹⁴, Judit Lluch¹⁵, Eva Galindez-Agirregoikoa¹⁶, Itziar Calvo-Zorrilla¹⁶, Vicente Aldasoro¹⁷, Javier Mendizabal¹⁸, LYDIA ABASOLO¹⁹, PIA LOIS²⁰, Javier Loricera¹³, Noemi Garrido-Puñal²¹, ALBERTO MARIANO RUIZ ROMAN²², Santos Castañeda²³, Cristina Valero²³, Patricia Moya Albarado²⁴, Hector Corominas²⁵, Maria J. García-Villanueva²⁶, Carmen Larena²⁷, Paula V. Estrada-Alarcón²⁸, Vanessa Navarro²⁹, Carles Galisteo³⁰, Anne Riveros-Frutos³¹, Francisco Miguel Ortiz Sanjuan³², Selene Labrada-Arrabal³³, María Alcalde³⁴, Clara Molina Almela³⁵, Carlos Garcia Porrua³⁶, Maria García-González³⁷, Margarida Rocha³⁸, Antonio Juan Mas³⁹, Miguel A Gonzalez-Gay⁴⁰ and Ricardo Blanco⁴¹, ¹Hospital Universitario de Bellvitge, Barcelona, Spain, ²Unidad de Investigación de la Sociedad Española de Reumatología, Madrid, Spain, ³Hospital do Meixoeiro. Complejo Hospitalario Universitario de Vigo, Vigo, Spain, ⁴CHU Vigo, O Carballino, Spain, ⁵Hospital Universitario La Paz, Madrid, Spain, ⁶University Hospital La Paz, Madrid, Spain, ⁷Rheumatology department, Complexo Hospitalario Universitario A Coruña (CHUAC). Instituto de Investigación Biomédica A Coruña (INIBIC)., A Coruña, Spain, ⁸Complejo Hospitalario Universitario de la Coruña, Pontevedra, Spain, ⁹University Hospital Donostia, Donostia-San Sebasti, Spain, ¹⁰Hospital Bidasoa, Irún, Spain, ¹¹Rheumatology, Hospital Universitario de León, León, Spain, ¹²Hospital Universitario de León, León, Spain, ¹³Hospital Universitario Marqués de Valdecilla, Santander, Spain, ¹⁴Hospital Universitario 12 de Octubre, Madrid, Spain, ¹⁵Department of Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ¹⁶Basurto University Hospital, Bilbao, Spain, ¹⁷Hospital Universitario de Navarra, Pamplona, Spain, ¹⁸Complejo Hospitalario de Navarra, Pamplona, Spain, ¹⁹Hospital Clínico San Carlos, Madrid, Spain, ²⁰Hospital Clinico San Carlos, Madrid, Spain, ²¹Hospital Universitario Virgen del Rocío, Sevilla, Spain, ²²Department of Rheumatology, Hospital Universitario Virgen del Rocío, Sevilla, Spain, ²³Hospital Universitario de la Princesa, Madrid, Spain, ²⁴Hospital Universitario de Sant Pau, Barcelona, Spain, ²⁵Hospital Universitario Sant Pau, Rheumatology, Barcelona, Spain, ²⁶Hospital Ramón y Cajal, Madrid, Spain, ²⁷Hospital Universitario Ramon y Cajal, Madrid, Spain, ²⁸Hospital de San Juan Despí Moisès Broggi, Barcelona, Spain, ²⁹Hospital de Sant Joan Despí – Moises Broggi, Barcelona, Spain, ³⁰Hospital Universitario Parc Taulí, Sabadell, Spain, ³¹Hospital Universitario Germans Trias i Pujol, Barcelona, Spain, ³²Hospital Universitario y Politecnico La Fe, Valencia, Spain, ³³Hospital del Mar, Barcelona, Spain, ³⁴Hospital Severo Ochoa, Madrid, Spain, ³⁵Hospital General de Valencia, Valencia, Spain, ³⁶Hospital Universitario Lucus Augusti, Lugo, Spain, ³⁷Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ³⁸Osakidetza, Bilbo, Spain, ³⁹Hospital Universitario Son Llàtzer, Mallorca, Spain, ⁴⁰IDIVAL and School of Medicine, UC, Santander; Department of Rheumatology, IIS-Fundación Jiménez Díaz, Madrid, Santander, Spain, ⁴¹Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: The relapse rate of treated patients with giant cell arteritis (GCA) varied widely in observational series and randomized controlled trials. This study aimed to…
Abstract Number: 2408 • ACR Convergence 2023
The Use of the Southend GCA Probability Score (GCAPS) in Assessing the Risk of Giant Cell Arteritis in Australian Ophthalmological and General Medical Hospital Cohorts
Eloise Norman¹, Clare Fraser², Mitchell Lawlor³ and Anthony Sammel⁴, ¹Prince of Wales Hospital, Randwick, Australia, ²Save Sight Institute, The University of Sydney, Sydney, Australia, ³Sydney and Sydney Eye Hospital, Sydney, Australia, ⁴The Prince of Wales Hospital, Sydney, Australia
Background/Purpose: The rate of positive temporal artery biopsies (TAB) in patients with suspected giant cell arteritis (GCA) varies widely, indicating the need for better pre-test…
Abstract Number: 2558 • ACR Convergence 2023
Aortic Aneurysms in a Multicenter Cohort of 196 Patients with Aortitis Related to Giant Cell Arteritis Treated with Tocilizumab
Fernando López¹, Javier Loricera², Adrián Martín-Gutiérrez³, Carmen Secada³, Santos Castañeda⁴, Clara Moriano Morales⁵, Javier Narvaez⁶, Vicente Aldasoro⁷, Olga Maiz⁸, Rafael Benito Melero-Gonzalez⁹, PALOMA VELA¹⁰, Susana Romero Yuste¹¹, Eugenio De Miguel¹², Eva Galindez-Agirregoikoa¹³, Jesús Carlos Fernández López¹⁴, Ivan Ferraz Amaro¹⁵, Julio Sánchez-Martín³, Jose L. Callejas¹⁶, Patricia Moya Albarado¹⁷ and Ricardo Blanco¹⁸, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²Hospital Universitario Marqués de Valdecilla, Santander, Spain, ³Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, ⁴Hospital Universitario de la Princesa, Madrid, Spain, ⁵Rheumatology, Hospital Universitario de León, León, Spain, ⁶Hospital Universitario de Bellvitge, Barcelona, Spain, ⁷Hospital Universitario de Navarra, Pamplona, Spain, ⁸Hospital Universitario de Donostia. San Sebastián, Spain., Donosti, Spain, ⁹CHU Vigo, O Carballino, Spain, ¹⁰Rheumatology, Hospital General Universitario Alicante, Alicante, Spain, ¹¹Complexo Hospitalario Universitario, Pontevedra, Spain, ¹²Hospital Universitario La Paz, Madrid, Spain, ¹³Basurto University Hospital, Bilbao, Spain, ¹⁴Rheumatology department, Complexo Hospitalario Universitario A Coruña (CHUAC). Instituto de Investigación Biomédica A Coruña (INIBIC), A Coruña, Spain, ¹⁵Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ¹⁶Unit of Systemic Autoimmune Diseases, Hospital San Cecilio, Granada, Spain, ¹⁷Hospital Universitario de Sant Pau, Barcelona, Spain, ¹⁸Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Aortic aneurysms is a serious complication that can occur in patients with giant cell arteritis (GCA) (1-2). Tocilizumab (TCZ) is approved for GCA. Nevertheless,…
Abstract Number: 0468 • ACR Convergence 2022
Ultrasound Wall Thickness in the Differential Diagnosis of Atherosclerosis and Large Vessel Giant Cell Arteritis
Eugenio De Miguel¹, Jose Maria Mostaza², Carlos Lahoz², Juan Molina³, Elisa Fernandez-Fernandez¹ and Irene Monjo⁴, ¹Hospital Universitario La Paz, Madrid, Spain, ²Hospital Carlos III, Madrid, Spain, ³Hospital General Universitario Gregorio Marañón, Madrid, Spain, ⁴Hospital Universitario La Paz - IdiPAZ, Madrid, Spain
Background/Purpose: Giant cell arteritis (GCA) is the most common vasculitis in the elderly and large vessel involvement (LV-GCA) occurs in up to 50% of cases.…
Abstract Number: 0484 • ACR Convergence 2022
Epidemiology and Predictors of Relapse in Giant Cell Arteritis: A Systematic Review and Meta-analysis
Lien Moreel¹, Albrecht Betrains¹, Geert Molenberghs², Steven Vanderschueren¹ and Daniel Blockmans¹, ¹University Hospitals Leuven, KU Leuven, Leuven, Belgium, ²KU Leuven, Leuven, Belgium
Background/Purpose: The aim of this study was to estimate the timing of relapse, the prevalence of multiple relapses and the predictors of relapse in patients…
Abstract Number: 1202 • ACR Convergence 2022
Clinical Profile and Trend of Vasculitis in Patients with Acute Coronary Syndrome – Insight from National Database 2010 to 2019
Palak Shah¹, Ana Arevalo², Rasha Alaameri³, Brinda Basida⁴, Urja Nagadia⁵, Sanket Basida⁵, shobhana Chaudhari⁶ and Monil Majmundar⁷, ¹Metropolitan Hospital Center, New York Medical College, New York, NY, ²University of Chicago, Chicago, IL, ³New York Medical College/ Metropolitan Program, New York, NY, ⁴DMC/Sinai Grace Hospital, Detroit, MI, ⁵University of Missouri, Columbia, MO, ⁶NYC Health and Hospital/Metropolitan Hospital, New York, NY, ⁷University of Kansas Medical Center, Kansas City, KS
Background/Purpose: Vasculitides are characterized by inflammation of vessel walls with reactive damage to mural structures leading to compromise of the lumen. Vasculitides also accelerate atherosclerosis…
Abstract Number: 0469 • ACR Convergence 2022
Factors Associated with Corticosteroid Dosing in the Management of Giant Cell Arteritis
Loukas Kakoullis and Shiv Sehra, Mount Auburn Hospital, Cambridge, MA
Background/Purpose: Corticosteroids are the cornerstone of therapy in patients with giant cell arteritis (GCA). Tapering regiments vary considerably in both dose and duration, while relapses…
Abstract Number: 0485 • ACR Convergence 2022
Assessing the Effectiveness of Tocilizumab in Newly Diagnosed Giant Cell Arteritis versus Refractory/recurrent Giant Cell Arteritis in Clinical Practice
Julio Sánchez-Martín¹, Javier Loricera², Clara Moriano³, Santos Castañeda⁴, F. Javier Narváez⁵, Vicente Aldasoro⁶, Olga Maiz⁷, Rafael Melero⁸, Juan Ignacio Villa Blanco⁹, Paloma Vela-Casasempere¹⁰, Susana Romero Yuste¹¹, José Luis Callejas¹², Eugenio De Miguel¹³, Eva Galíndez-Agirregoikoa¹⁴, Francisca Sivera¹⁵, Jesus Fernandez¹⁶, Carles Galisteo¹⁷, Ivan Ferraz Amaro¹⁸, Lara Sánchez-Bilbao¹, Monica Calderon-Goercke¹⁹, Miguel Ángel González-Gay²⁰ and Ricardo Blanco², ¹Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ³Complejo Asistencial Universitario de León, León, Spain, ⁴Division of Rheumatology, Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Spain, ⁵Rheumatology Department, Hospital Universitario de Bellvitge, Barcelona, Spain, ⁶Hospital Universitario de Navarra, Pamplona, Spain, ⁷Hospital Universitario de Donostia, San Sebastián, Spain, ⁸Complexo Hospitalario Universitario de Vigo, Vigo, Spain, ⁹Sierrallana Hospital, Torrelavega, Spain, ¹⁰Hospital General Universitario Alicante, Alicante, Spain, ¹¹Complexo Hospitalario Universitario, Pontevedra, Spain, ¹²Hospital San Cecilio, Granada, Spain, ¹³Hospital Universitario La Paz, Madrid, Spain, ¹⁴Basurto University Hospital, Bilbao, Spain, ¹⁵Hospital Universitario de Elda, San Vicente del Raspeig, Spain, ¹⁶Hospital de La Coruña, La Coruña, Spain, ¹⁷Hospital Parc Tauli,, Sabadel, Spain, ¹⁸Division of Rheumatology. Hospital Universitario de Canarias. Spain., Santa Cruz de Tenerife, Spain, ¹⁹Hospital de Sierrallana, Torrelavega, Spain, ²⁰Department of Medicine and Psychiatry, Universidad de Cantabria; Rheumatology Division, Hospital Universitario Marqués de Valdecilla; Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic diseases of the musculoskeletal system, IDIVAL, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
Background/Purpose: Tocilizumab (TCZ) is the only biologic drug approved in giant cell arteritis (GCA), based in two clinical trials (CT) (1,2). CT included selected patients…
Abstract Number: 1245 • ACR Convergence 2022
Imaging Use and Medication Management in Giant Cell Arteritis
Aradhna Agarwal¹, Reid Weisberg¹, Jiby Mathew², Andreas Reimold³ and Kyawt Shwin¹, ¹UT Southwestern, Dallas, TX, ²VA North Texas Health Care System/Dallas VA Medical Center, Dallas, TX, ³University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: Giant cell arteritis (GCA) affects medium and large arteries. Although temporal artery biopsy (TAB) remains the gold standard for patients with cranial GCA, patients…
Abstract Number: 0470 • ACR Convergence 2022
Long-term Efficacy of Tocilizumab Monotherapy After Ultra-short Glucocorticoid Administration to Treat Giant Cell Arteritis – One Year Follow-up of the GUSTO Trial
Lisa Christ¹, Luca Seitz², Godehard Scholz¹, Lukas Buetikofer³, Florian Kollert¹, Stephan Reichenbach⁴ and Peter Villiger⁵, ¹Department of Rheumatology and Immunology, University of Bern, Inselspital, Bern, Switzerland, ²Department of Rheumatology and Immunology, University of Bern, Inselspital, Switzerland, ³CTU Bern, University of Bern, Bern, Switzerland, ⁴University of Bern, Institute for Social and Preventive Medicine, Bern, Switzerland, ⁵Medical Center Monbijou, Rheumatology and Immunology, Bern, Switzerland
Background/Purpose: Two randomised controlled trials (RCT) [1, 2] demonstrated a glucocorticoid (GC)-sparing effect of tocilizumab (TCZ) of at least 50% in the treatment of giant…
Abstract Number: 0486 • ACR Convergence 2022
Gene Expression Profile of Temporal Artery Tissue and Whole Blood in Giant Cell Arteritis
Marcia Friedman¹, Daniel Albert², Dongseok Choi³, Hillary Stiefel², Colin Oglesbee-Venghaus², Kimberly Ogle², Christina Harrington⁴, David Wilson² and James T. Rosenbaum⁵, ¹Oregon Health and Science University, Division of Arthritis and Rheumatic Diseases, Portland, OR, ²Casey Eye Institute, Portland, OR, ³OHSU-PSU School of Public Health, Portland, OR, ⁴Oregon Health & Science University, Portland, OR, ⁵Legacy Devers Eye Institute, Portland, OR
Background/Purpose: Diagnosing giant cell arteritis GCA is notoriously challenging, as there are no reliable blood biomarkers and temporal artery biopsy (TAB) has a sensitivity of…
Abstract Number: 1257 • ACR Convergence 2022
Assessing the Effectiveness of Tocilizumab in Giant Cell Arteritis by PET: Multicenter Study of 101 Patients of Clinical Practice
Julio Sánchez-Martín¹, Javier Loricera¹, Santos Castañeda², Clara Moriano³, F. Javier Narváez⁴, Vicente Aldasoro⁵, Olga Maiz⁶, Rafael Melero⁷, Juan Ignacio Villa Blanco⁸, Paloma Vela-Casampere⁹, Susana Romero Yuste¹⁰, José Luis Callejas¹¹, Eugenio De Miguel¹², Eva Galíndez-Agirregoikoa¹³, Francisca Sivera¹⁴, Jesus Fernandez¹⁵, Carles Galisteo¹⁶, Ivan Ferraz Amaro¹⁷, Lara Sánchez-Bilbao¹, Monica Calderon-Goercke¹⁸, Miguel Ángel González-Gay¹⁹ and Ricardo Blanco²⁰, ¹Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²Division of Rheumatology, Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Spain, ³Complejo Asistencial Universitario de León, León, Spain, ⁴Rheumatology Department, Hospital Universitario de Bellvitge, Barcelona, Spain, ⁵Hospital Universitario de Navarra, Pamplona, Spain, ⁶Hospital Universitario de Donostia, San Sebastián, Spain, ⁷Complexo Hospitalario Universitario de Vigo, Vigo, Spain, ⁸Sierrallana Hospital, Torrelavega, Spain, ⁹Hospital General Universitario Alicante, Alicante, Spain, ¹⁰Complexo Hospitalario Universitario, Pontevedra, Spain, ¹¹Hospital San Cecilio, Granada, Spain, ¹²Hospital Universitario La Paz, Madrid, Spain, ¹³Basurto University Hospital, Bilbao, Spain, ¹⁴Hospital Universitario de Elda, San Vicente del Raspeig, Spain, ¹⁵Hospital de La Coruña, La Coruña, Spain, ¹⁶Hospital Parc Tauli,, Sabadel, Spain, ¹⁷Division of Rheumatology. Hospital Universitario de Canarias. Spain., Santa Cruz de Tenerife, Spain, ¹⁸Hospital de Sierrallana, Torrelavega, Spain, ¹⁹Department of Medicine and Psychiatry, Universidad de Cantabria; Rheumatology Division, Hospital Universitario Marqués de Valdecilla; Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic diseases of the musculoskeletal system, IDIVAL, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, ²⁰Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Positron emission tomography (PET) is one of the tools available for the diagnosis of extracranial large-vessel vasculitis (1-5). Tocilizumab (TCZ) has shown efficacy in…
Abstract Number: 0471 • ACR Convergence 2022
Serum Proteomics in Giant Cell Arteritis: Findings of the Giant Cell Arteritis Treatment with Ultra-short Glucocorticoids and Tocilizumab Trial (The GUSTO Trial)
Lisa Christ¹, Andrea Gloor², Florian Kollert¹, Timo Gaber³, Frank Buttgereit³, Stephan Reichenbach⁴ and Peter Villiger⁵, ¹Department of Rheumatology and Immunology, University of Bern, Inselspital, Bern, Switzerland, ²Department of Internal Medicine, University of Bern, Inselspital, Bern, Switzerland, ³Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin / DRFZ Berlin, Berlin, Germany, ⁴University of Bern, Institute for Social and Preventive Medicine, Bern, Switzerland, ⁵Medical Center Monbijou, Rheumatology and Immunology, Bern, Switzerland
Background/Purpose: Measuring disease activity in patients with giant cell arteritis (GCA) remains challenging since appropriate biomarkers are missing, particularly, if tocilizumab (TCZ) is prescribed which…

« Previous Page
1
…
8
9
10
11
12
…
32
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].